Search research articles
Contact Us
Filters
Showing results (161-170 of 205) with videos related to
Page
of 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2008
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
Michael C Heinrich, Heikki Joensuu, George D Demetri, et al.
Cancer Research
|
June 3, 2004
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer
Mark A Rubin, Sooryanarayana Varambally, Rameen Beroukhim, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 21, 2011
Aberrant AKT activation drives well-differentiated liposarcoma
Alejandro Gutierrez, Eric L Snyder, Adrian Marino-Enriquez, et al.
The New England Journal of Medicine
|
April 4, 2014
Thyroid hormone inactivation in gastrointestinal stromal tumors
Michelle A Maynard, Adrian Marino-Enriquez, Jonathan A Fletcher, et al.
Oncotarget
|
June 6, 2014
Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors
Chun-Nan Yeh, Chueh-Chuan Yen, Yen-Yang Chen, et al.
British Journal of Cancer
|
February 23, 2019
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
César Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure
George D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Molecular Cancer Therapeutics
|
July 17, 2019
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy
Thomas Mühlenberg, Julia Ketzer, Michael C Heinrich, et al.
British Journal of Cancer
|
May 25, 2019
Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
César Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
BMC Cancer
|
February 7, 2020
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
César Serrano, Ana Vivancos, Antonio López-Pousa, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 205) with videos related to
Sort By:
Page
of 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2008
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
Michael C Heinrich, Heikki Joensuu, George D Demetri, et al.
Cancer Research
|
June 3, 2004
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer
Mark A Rubin, Sooryanarayana Varambally, Rameen Beroukhim, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 21, 2011
Aberrant AKT activation drives well-differentiated liposarcoma
Alejandro Gutierrez, Eric L Snyder, Adrian Marino-Enriquez, et al.
The New England Journal of Medicine
|
April 4, 2014
Thyroid hormone inactivation in gastrointestinal stromal tumors
Michelle A Maynard, Adrian Marino-Enriquez, Jonathan A Fletcher, et al.
Oncotarget
|
June 6, 2014
Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors
Chun-Nan Yeh, Chueh-Chuan Yen, Yen-Yang Chen, et al.
British Journal of Cancer
|
February 23, 2019
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
César Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure
George D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Molecular Cancer Therapeutics
|
July 17, 2019
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy
Thomas Mühlenberg, Julia Ketzer, Michael C Heinrich, et al.
British Journal of Cancer
|
May 25, 2019
Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
César Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
BMC Cancer
|
February 7, 2020
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
César Serrano, Ana Vivancos, Antonio López-Pousa, et al.
Page
of 21